The Italian Society of Interventional Cardiology consensus recommends aspirin and clopidogrel as the preferred dual antiplatelet therapy to prevent stent thrombosis after coronary stenting.
Answers are grounded in this paper and cite their sources.
Recommends aspirin-clopidogrel DAPT to prevent stent thrombosis; reinforces established guidelines for post-stenting care.
The Italian Society of Interventional Cardiology is aware of the existence of significant local and individual disparities and discordant prescriptions in antiplatelet therapy administered with coronary stents, a critical issue due to the large use of drug-eluting stents (DES), the increasing complexity of percutaneous coronary interventions and the more stringent requirement to avoid stent thrombosis. Current percutaneous coronary intervention is attempting more aggressively to treat difficult lesions and patient cohorts with a high procedural success rate. Double antiplatelet therapy with aspirin (ASA) and thienopyridine is the best current treatment to reduce the risk of coronary stent thrombosis. Due to the lower incidence of side-effects compared to ticlopidine, clopidogrel should be the thienopyridine of choice in association with ASA in the double antiplatelet regimen. However, the combination of delayed healing with DES and the increasing complexity of the stent implantation raises more demanding safety concerns about the dosage and duration of dual antiplatelet therapy.
No takes yet. Share an insight, caveat, or question.
Guagliumi et al. (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: